Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cognis

This article was originally published in The Tan Sheet

Executive Summary

Most or all of the nutritionals, ingredients and chemicals company could be on the selling block, parent company Henkel Group announces Nov. 13. Dusseldorf, Germany-based Henkel split its chemical products business off to form Cognis earlier this year intending to seek a minority partner, but now says it has been unable to secure an advantageous deal (1"The Tan Sheet" Feb. 14, In Brief). Henkel wants to divert resources from Cognis - which accounts for 23% of the firm's worldwide business - to focus on consumer products. The firm stresses any moves made involving Cognis are unrelated to its desire to acquire the Clairol hair care franchise from Bristol-Myers Squibb (2"The Tan Sheet" Oct. 2, p. 5)

You may also be interested in...



Cognis

Henkel Group's nutritionals, ingredients and chemicals division revenues increased 12% to $2.73 bil. in 2000, not including about $247.7 mil. in sales to other Henkel units. Operating profit rose almost 23% to $205.6 mil. Cognis' Oleochemicals business sector, encompassing the Nutrition & Health unit, reported a 15% gain to $887.9 mil., with strong growth in worldwide dietary supplement market helping to offset U.S. slowdown. Created when Henkel carved out its chemical products business in August 1999, Cognis accounts for 23% of its parent's overall sales. Henkel execs say they are moving forward with plans to sell part or all of division (1"The Tan Sheet" Nov. 20, 2000, In Brief)

Cognis

Henkel Group's nutritionals, ingredients and chemicals division revenues increased 12% to $2.73 bil. in 2000, not including about $247.7 mil. in sales to other Henkel units. Operating profit rose almost 23% to $205.6 mil. Cognis' Oleochemicals business sector, encompassing the Nutrition & Health unit, reported a 15% gain to $887.9 mil., with strong growth in worldwide dietary supplement market helping to offset U.S. slowdown. Created when Henkel carved out its chemical products business in August 1999, Cognis accounts for 23% of its parent's overall sales. Henkel execs say they are moving forward with plans to sell part or all of division (1"The Tan Sheet" Nov. 20, 2000, In Brief)

Cognis

Henkel Group's nutritionals, ingredients and chemicals division revenues increased 12% to $2.73 bil. in 2000, not including about $247.7 mil. in sales to other Henkel units. Operating profit rose almost 23% to $205.6 mil. Cognis' Oleochemicals business sector, encompassing the Nutrition & Health unit, reported a 15% gain to $887.9 mil., with strong growth in worldwide dietary supplement market helping to offset U.S. slowdown. Created when Henkel carved out its chemical products business in August 1999, Cognis accounts for 23% of its parent's overall sales. Henkel execs say they are moving forward with plans to sell part or all of division (1"The Tan Sheet" Nov. 20, 2000, In Brief)

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091901

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel